These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4878452)

  • 21. Inhibition of the gastrointestinal absorption of p-aminosalicylate (PAS) in rats and humans by diphenhydramine.
    Lavigne JG; Marchand C
    Clin Pharmacol Ther; 1973; 14(3):404-12. PubMed ID: 4698569
    [No Abstract]   [Full Text] [Related]  

  • 22. [Blood concentration of basic tuberculostatic preparations with single administration of daily doses in pulmonary tuberculosis].
    Kanevskaia SS
    Probl Tuberk; 1970; 48(10):54-8. PubMed ID: 5496751
    [No Abstract]   [Full Text] [Related]  

  • 23. [Biopharmaceutical studies on the influence of vehicles on resorption of drugs from dosage forms. 2. Intestinal resorption of sodium paraaminosalicylate from aqueous solutions in the presence of surface active and macromolecular vehicles].
    Körössyová Z; Zathurecký L
    Pharmazie; 1971 Nov; 26(11):682-5. PubMed ID: 5154322
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of mycobactin formation in Mycobacterium smegmatis by p-aminosalicylate. A new proposal for the mode of action of p-aminosalicylate.
    Ratledge C; Brown KA
    Am Rev Respir Dis; 1972 Nov; 106(5):774-6. PubMed ID: 5078877
    [No Abstract]   [Full Text] [Related]  

  • 25. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
    Osterman MT; Lichtenstein GR
    Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Para-aminosalicylic acid metabolism in the body. VII. Resorption and tolerance of calcium-PAS compound and early results of treatment of pulmonary tuberculosis].
    Owsiński J; Kamińska M; Ostrowska A; Rapf T
    Gruzlica; 1972 Jul; 40(7):635-7. PubMed ID: 5053842
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of humidity aging on disintegration, dissolution an cumulative urinary excretion of calcium p-aminosalicylate formulations.
    Kadir S; Yata N; Kawata M; Goto S
    Chem Pharm Bull (Tokyo); 1986 Dec; 34(12):5102-9. PubMed ID: 3568212
    [No Abstract]   [Full Text] [Related]  

  • 29. The influence of para-aminosalicylic acid on isonicotinic acid hydrazide blood levels after oral and intravenous administration.
    Kreukniet J; Blom van Assendelft PM; Mouton RP; Tasman A; Bangma PJ
    Scand J Respir Dis; 1966; 47(4):236-43. PubMed ID: 5182291
    [No Abstract]   [Full Text] [Related]  

  • 30. [Stability of sodium p-aminosalicylate in the solid state].
    Wang PY; Zhang QM; Li GH; Fu YK; Xu YD; Yuan FL
    Yao Xue Xue Bao; 1983 Oct; 18(10):786-9. PubMed ID: 6677035
    [No Abstract]   [Full Text] [Related]  

  • 31. [STUDIES ON THE ANALYTICAL APPLICATION OF ANTIPYRINE DERIVATIVES. (2) COLORIMETRIC DETERMINATION OF M-AMINOPHENOL IN SODIUM OR CALCIUM P-AMINOSALICYLATE WITH 4-FORMYLANTIPYRINE].
    MORITA M
    Eisei Shikenjo Hokoku; 1963 Oct; 81():1-3. PubMed ID: 14162023
    [No Abstract]   [Full Text] [Related]  

  • 32. [CHLOROCOULUMETRIC MICRODETERMINATION OF THE SODIUM, POTASSIUM AND DICALCIUM SALTS OF P-AMINOSALICYLIC ACID].
    KALINOWSKI K; ZWIERZCHOWSKI Z
    Acta Pol Pharm; 1963; 20():303-8. PubMed ID: 14059256
    [No Abstract]   [Full Text] [Related]  

  • 33. [Isolation of strain Pseudomonas sp. ASA2 from a methanogenic community degrading aminobenzoate and aminosalicylate].
    Savel'eva OV; Kotova IB; Skliar VI; Kaliuzhnyĭ SV; Netrusov AI
    Mikrobiologiia; 2002; 71(2):281-2. PubMed ID: 12024833
    [No Abstract]   [Full Text] [Related]  

  • 34. [On the hypokaliemic effects of sodium-p-aminosalicylate].
    Pankow D; Peters JE
    Med Pharmacol Exp Int J Exp Med; 1965; 13(5):312-6. PubMed ID: 5898536
    [No Abstract]   [Full Text] [Related]  

  • 35. [The demonstration of 5-aminosalicylic acid as a contaminant of sodium aminosalicylate].
    Vlezenbeek HJ
    Pharm Weekbl; 1966 Sep; 101(38):841-2. PubMed ID: 5980337
    [No Abstract]   [Full Text] [Related]  

  • 36. [Concentration and tolerance of INH and PAS in single daily doses. (Preliminary report)].
    Vil'derman AM; Finn ER; Busygina RN; Draganiuk KA; Ezerskiĭ VF; Evgrafova ZA
    Probl Tuberk; 1965; 43(11):30-4. PubMed ID: 5875728
    [No Abstract]   [Full Text] [Related]  

  • 37. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
    Hanauer SB
    Am J Gastroenterol; 2003 Jan; 98(1):215-6. PubMed ID: 12526968
    [No Abstract]   [Full Text] [Related]  

  • 38. Review article: aminosalicylates for distal colitis.
    Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():41-4. PubMed ID: 16961744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of toleration and absorption of phenyl p-aminosalicylate with several p-aminosalicylic acid preparations.
    COHEN SS; YUE WY; TSAI SH
    Antibiot Annu; 1958-1959; 6():121-4. PubMed ID: 13637719
    [No Abstract]   [Full Text] [Related]  

  • 40. [Utilization in the treatment of tuberculosis in children of a single daily oral dose of isoniazid and para-aminosalicylic acid].
    Sarrouy C; Viallier J; Vaillaud JC
    Ann Pediatr (Paris); 1967 Mar; 14(3):219-24. PubMed ID: 5614546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.